EUROTOX 2018 ControlCenter

Online Program Keyword Index

To search for a specific ID please enter the hash sign followed by the ID number (e.g. #123).
Keyword Contributions
(bio)transformation CEC5-01
(eco)toxicity P19-14
(q)ivive P12-35
(q)sar P05-12
1-bromopropane P20-13
1r P19-05
2-diacetylbenzene P13-15
2-methoxymethyl-p-phenylenediamine (me-ppd) P13-19
2.6-dimethylpyridine-n-oxide P11-20
21st century S22-01
2_4-d P04-08
2’-fucosyllactose P10-29
3-mcpd P10-13
3-nba P07-47
3d -scaffold P06-17
3d bioprinting P07-18
3d cell culture P07-47
3d cell system S06-03
3d culture P07-19
3d cultures P03-12P25-12
3d human liver microtissues P01-27
3d human skin model OP03-05
3d in vitro model P12-34
3d in vitro models CEC4-05P07-33
3d lung models P07-10
3d microtissues P18-03
3d model P07-41
3d modeling P06-02
3d organoids P07-17Symp01-05
3d organotypic P07-11
3d renal proximal tubule cell (rptec) model OP03-09
3d skin model OP03-07
3d skin model-based assays OP03-03
3r P01-33P01-36P22-09
3rs KN 2P01-25P06-15P19-05
3r’s P01-35
4-dichlorophenoxyacetic acid P23-10
4-fluoromethamphetamine (4-fma) P16-20
4-hydroxybenzoate P25-11
5'-utr area P18-12
90-day toxicity P10-29
a549 ArrayArrayArrayArray
a549 cells P17-17P17-28
ab initio P12-35
abc transporters ArrayArrayArrayArrayArrayArrayArrayArray
abcg2/bcrp P07-29
abuse S20-04
abuse liability P25-08
acephate P16-31
acer tegmentosum extract P11-18
acetaminophen P07-04P16-33P18-06OP03-02
acetaminophen hepatotoxicity S21-01
acetamiprid P02-03
acetylcholine P25-10
acetylcholinesterase P10-20
ache activity P25-41
acid-hydrolyzed wheat protein P13-16
acrolein ArrayArrayArrayArray
activation ArrayArrayArrayArray
acute fish toxicity P17-07
acute hazards S02-05
acute lung injury P07-35
acute toxicity P22-10
ada P19-28
adequacy P19-26
adipogenesis S27-03
adiponectin P04-08
adma P23-17
adme P19-12P24-15S05-03
admet P05-20
advanced in vitro models S07-02
adverse effects P22-01
adverse outcome pathway CEC6-01EU-ToxRisk-1P23-16S14-01S14-02S17-04
adverse outcome pathway (aop) P05-13P12-42S23-01
adverse outcome pathways CEC6-02P12-23P19-25S17-01S17-02
aerosols S07-01
aerrosol trapping P16-08
aflatoxin b1 P07-11
aflatoxin m1 P10-27
aflatoxins P12-13
age P13-08
age-related immunotoxicity S25-01
ageing S13-05
aggregate exposure CEC1-05CEC1-06
aggregated exposure CEC1-01
aggregation P17-10OP03-06
aging indicator P10-01
agrochemcial P11-14
ah receptor P16-45
ahr P16-45P20-03S03-04S03-05
air pollution P12-22P16-19S13-01S13-03S13-04S13-05S03-05
air quality P12-46
air-blood barrier P19-17OP03-08
air-lifted interface P01-02
air-liquid interface exposure P17-28
air-liquid-interface P01-28
airborne particles P12-11
airway P01-18
airway disease P17-27
airway epithelium CEC4-03
alamar blue assay P10-03
alcohol P23-22
alginate P25-40
ali P07-41
aliphatic alcohols P12-06
alkaloids P12-01
alkanes P12-06
allegy P17-27
allergenicity P10-07
allergenicity prediction P01-19
allergens S07-03
allergic contact dermatitis P01-22P05-07OP03-01
allergies P09-02
allergy P10-26P13-01P13-03
allium cepa P17-23P17-24
allopurinol P04-02
alt4ei P07-28
alternaria alternata P22-03
alternariol P22-03
alternative ArrayArrayArrayArray
alternative animal models P16-35OP02-01
alternative approach P12-42
alternative flame retardant P12-34
alternative method P01-26P13-04
alternative methods P01-15P01-33P05-07S06-05OP02-05
alternative model P16-48
alternative models P01-08P01-32
alternative risk assessment P12-10
alternative testing methods S17-04
alternative to animal testing P07-42
alternatives P01-09P01-12P18-11P19-05S08-04
alternatives for animal testing P01-36
alternatives to animal testing S01-01S02-04
alternatives to animals CEC3-06
altertoxin ii (atxii) P10-21
aluminum P16-05
alveolar barrier OP03-08
alveolar type i cell P12-12
alzheimer's disease ArrayArrayArrayArray
ames P10-25P11-07
ames assay P11-09
ames test P11-18
amniotic fluid P02-15P09-03
amphibian P12-44
anaemia P25-03
analogue approach P12-10
analytical toxicology P25-10P25-20
and gills P12-51
angiogenesis P03-03P08-04S17-03
animal S15-01
animal free assays S23-03
animal health S14-04
animal models P01-04
animal poisoning P25-27
animal welfare P19-09
animal-free P24-12
animals models P01-29
anionic and cationic uptake ArrayArrayArrayArray
anogenital distance OP02-02
ansm P19-28
antagonistic P08-01
anti-bpde-dna P11-04
anti-cancer P20-01
anti-cancer agent P06-03
anti-inflammatory P13-22
anti-obesity drugs Symp01-07
antiandrogens P08-11
antibody-drug conjugates P19-28
anticholinesterases P25-27
antidepressant P25-32
antidotal pathway ArrayArrayArrayArray
antidote P17-21P19-19
antimicrobial peptide P01-02
antimicrobials P13-23
antineoplastic P12-29
antioxidant P02-11P11-16P16-30
antioxidant capacity P02-04
antioxidant enzyme P16-29
antioxidants P16-21P23-20P23-21
antisense oligodeoxynucleotides S05-04
antisense oligonucleotides S05-02
antothrombotic effect P19-18
anxiety P20-12
anxiolytic P25-32
aop CEC1-04P07-12P08-15P16-23P23-14P24-03S23-03S08-02OP01-05OP02-09Symp01-01
aop wiki S09-04
aop-kb S17-04
aops S02-03
apoferritin P03-09
apoptosis P02-07P03-10P06-09P10-28P20-01P23-08P25-36
apoptotic P11-08
approved biocidal active substances P12-47
aqps P01-30
aquatic toxicity P19-09
aqueous extract P22-05
aroylhydrazones P05-21
arsenic compounds P20-01
aryl hydrocarbon receptor P08-01P16-07S22-04S03-05
aso S05-02
assay ready cells P01-17
assessment P12-27P19-14
assessment element CEC5-01
assessment factor P12-06S18-03
association Symp01-01
asthma P17-27
astrocyte S12-03
atp rate assay ArrayArrayArrayArray
attrition S24-02
auditory brainstem response (abr) P01-06
autism P04-04OP01-07
automated behavioural analysis S20-01
autophagy P16-21P16-34
autophagy inhibitors P16-21
autopsy case P04-01
aviation emission P12-16
award P19-05
azoles P16-22
b cell activating factor P13-11
b[a]p P07-47
baby wipes P19-08
background data P19-11
baikal seal P08-07
balb/c P12-45
bath salts P23-06
battery ingestion P04-05
bay of bengal coast P12-50
bayesian model P13-05
bayesian modelling P10-05
bayesian net P01-05
bcop P07-39
bcop llbo P07-28
bde-209 P22-04
behavior P20-12
behavioral testing. P25-26
behaviour P17-04S20-01
benchmark dose CEC2-03CEC2-05
benchmark dose (bmd) S08-03
benchmark dose modelling CEC2-06
benzene P16-16
benzo(a)pyrene P16-45
benzo[a]pyrene P03-06P11-27P18-10
benzo[a]pyrene,neural cell apoptosis,atm,chk2,p53 P16-11
betulinic acid P06-26
bibliometric analysis P12-08
big data HESI CITE-1P05-26Symp01-01
bile acid P06-09
bile acids S19-02
bioaccumulation P12-26
bioactivation Symp01-03
bioassay toolbox OP02-09
bioassays P12-23
bioavailability P01-11P01-14
biochemical parameters P23-10
biochip array P19-04
biochips S06-04
biocidal products regulation P12-47
biocompartibility P07-42
biocompatible surface coatings P13-23
biocorrosion P16-04
biodegradability P12-21
biodistribution P06-03
bioinformatics S12-02OP02-01
biokinetics P24-03S09-02
biological clock P06-24
biological incidents training P25-05
biological membranes P17-01
biological networks P05-10
biologics S04-02OP03-06
biomarker P02-02P02-06P02-09S13-03S19-01Symp01-04
biomarker panels S19-04
biomarkers P02-03P02-07P02-14P07-10P12-22P12-28P16-19P20-11P23-19S19-03S23-03OP01-06
biomaterials P07-18
biomechanics P07-35
biomonitoring P09-01P09-03
bioprotectors P24-01
biosensor P25-10
biotherapeutics S16-02
birth weight P20-02
bispenols CEC1-01
bisphenol a P08-03P13-11P18-08P19-02P20-09P22-08
bisphenol analog P08-07
bisphenol s P18-08
bisphenol-a P08-13
bisphenols CEC1-06P09-03
bitumen fumes P11-04
bladder cancer P25-14
blood P12-51P25-01
blood lead concentration P09-01
blood-brain barrier OP03-10
bmd CEC2-04
bmd approach CEC2-01CEC2-02
bmds CEC2-03
bmr CEC2-02
bnf P20-03
bo-smcs P07-01
boecs P07-01
bone marrow Symp01-10
botanicals ArrayArrayArrayArrayP12-02
bpa P08-12
bps P08-02
brachydanio rerio P01-29
brain P16-07
brain development P12-32S27-02
brake dust P12-43
brdu-elisa P12-45
breast cancer P03-02P03-03P03-04P03-12P06-26P11-23
bronchial tissues P07-11
bsep inhibition P07-48
btx P12-46
bursary P19-05
button battery ingestion P04-05
butyrylcholinesterase P25-36
bystander CEC1-05
bystander substances S07-03
bzp P04-06
c. elegans P10-01
caco-2 ArrayArrayArrayArray
caco-2 cells P17-17
caco-2/ht29-mtx cell co-culture P17-15
caenorhabditis elegans P01-35
caffeine P06-27P16-33
caffeine-alginate methylsilanetriol P11-24P11-25
calcium P02-11
calcium transients P23-04
calendula officinalis P12-24
camel thorn P25-39
cancer P06-22P07-32P10-28S11-01S03-01
cancer bioassay S22-01
cancer cells ArrayArrayArrayArray
cancer immunosuppression S03-04
canines P23-19
cannabinoid receptors ArrayArrayArrayArray
capsaicin P25-40
capture of unintentional sequences OP01-08
carbon nanotube P17-19
carbon nanotubes P17-01P17-22OP01-02
carcinogenesis P03-04P03-08P07-22P11-17P11-21P12-42S
carcinogenicity P16-32P19-22P19-23
carcinogenicity assay P01-32
carcinogenicity testing P03-11
cardiac action potential Symp01-06
cardiac safety P07-46S24-02
cardiac toxicity S24-02
cardio- and nephrotoxicity S19-04
cardio-oncology P07-32
cardiomyocytes ArrayArrayArrayArrayP07-46S24-03
cardiotoxicity ArrayArrayArrayArrayArrayArrayArrayArrayArrayArrayArrayArrayP02-02P04-06P05-19P06-15P07-46P16-44P23-04S24-04S06-04OP01-06
cardiovascular P22-01
cardiovascular earlier detection HESI CITE-1
cardiovascular safety P06-12
carnosic acid P08-12
case studies CEC2-06
case study P12-10S02-06
category P05-17
cb1 receptor ArrayArrayArrayArray
cba/j P12-45
cblb502 P07-03
ccl4 intoxication P02-07
cd P22-04
cd40l S01-03
cddp ArrayArrayArrayArray
cdisc P19-01
celecoxib P13-22
cell cycle P11-02P17-03
cell death P16-43
cell differentiation P25-25
cell functionality P07-19
cell imaging P06-05
cell invasion P08-04
cell lines ArrayArrayArrayArray
cell lines. cancer. cytotoxicity. P06-10
cell membrane P10-21
cell migration P08-04
cell painting P16-49
cell proliferation S22-04S
cell transformation P03-06
cell viability P16-13P20-08P23-06
cell-to-cell communication S22-04
cellculture S07-01
cells of the glía P06-27
cellular metabolism P07-14
central activity P17-04
ceramic nanoparticles P17-28
cerebellum OP01-07
cetacean P07-06
characterization P07-17P17-18
chemical analysis P13-03
chemical carcinogens S22-02
chemical contaminants P10-15
chemical mixtures S14-04
chemical risk assessment S02-01
chemical safety assessment P01-09P12-06
chemical screening S10-02
chemical transport models S13-01
chemical-specific adjustment factor OP02-04
chemically-induced transgenic state P18-09
chemicals' mixtures S26-04
chemiluminescence P16-18
chemistry P05-13
chemistry dashboard S09-04
chemoinformatics OP02-01
chemoprevention P03-01P03-06
chemopreventive P16-43
children P04-05
chlorophenoxyacetic acid P16-29
chlorpyrifos P03-02P03-03P25-36
cho P11-26
cholestasis P07-48P10-11OP01-04
cholinergic system P25-41
cholinesterase P16-38
chromosomal aberrations P11-03
chromosome aberration test P11-18
chromosome aberrations P11-20P17-24
chronic effects P02-03
chronic ethanol consumption P16-17
chronic exposure P10-01P12-49
chronic kidney disease P23-07
chrysotile P12-43
cigarette P16-27
cigarette smoke P01-01P16-08P18-05P22-06P23-08
cigarette smoking P22-01
cilia beat frequency P07-24
cipa KN 2S24-03
ciprofloxacin P06-04
citespace P12-08
citotoxicity P11-24
classification P05-15P05-16P19-14
clastogenicity P05-20
claudin-2 P06-03
cleaning P25-38
cleaning products P12-38
climate change P12-13
clinical S24-01
clinical trial P11-02
cns P06-16S06-03
cns drugs S12-04
cns safety S20-01
co-culture CEC4-05
co-occurrence P10-23
coagulation P19-18
cocaine ArrayArrayArrayArrayP06-27
coculture P12-09
coenzyme q10 P20-09
coexposure CEC1-03
cognition S13-04
colon cancer K-01P10-12
colorectal cancer P10-09S11-02
colorectal carcinogenesis P03-01
colorimetry P25-10
combinatory effects P22-03
combined oral contraceptives OP02-07
combustion particles S13-03
comet assay P11-05P11-06P11-10P11-13P11-22P12-36
commercial engineered nanostructured materials P17-07
comparative and combined toxicity P24-01
computational P05-04P12-30
computational biology ArrayArrayS23-04S08-01
computational infrastructure P05-25
computational model P05-05
computational modelling P05-20
computational toxicology P05-03P05-07P05-09P05-13P05-24P05-26P24-13OP02-06
computationally predicted adverse outcome pathways P05-22
computional toxicology S23-03
con4ei P07-28
condensed aerosols P19-17
conditioned medium P03-12
confocal imaging P16-23
conformal predictions P07-36
consensus models OP02-06
constitutive androstane receptor S22-03
consumer product safety P12-39
consumer products P12-38
consumers protection S26-04
contact allergens S21-03
container-content interactions P12-19
contamination S07-03
continued professional development P25-16
continuous data CEC2-02
contractility P07-46
contrast-induced nephropathy P23-17P23-20P23-21
control antibodies S28-02
controlled terminology (ct) P19-01
convection-enhanced delivery P19-03
corneal epithelium P07-42
cosmetic ingredient P01-10
cosmetic product P12-33
cosmetics P12-19P19-08P25-37S02-06
cosmos S09-02
cost P19-19
cotinine P02-13P25-32
crocidolite P12-43
cross-sectional study P09-04
crosstalk effects P24-11
cryptochrome P06-24
ctx-m P12-41
cumulative risk CEC1-06
cumulative risk assessment CEC1-04P10-02
cuo nanoparticles P13-23
cyclin d1 P11-08
cyclophosphamide P11-20
cylindrospermopsin P10-08P11-10
cynomolgus monkeys P06-08
cyp K-01
cyp enzymes P16-03
cyp3a4-related uncertainty factor P24-10
cyp450 P02-10
cyprinus carpio P12-51
cyproconazole OP02-09
cyprotex P16-42
cytochemical P20-06
cytochrome p450 P01-34P07-05
cytogenetic activity P11-20
cytokine S28-03
cytokine release S28-01S28-04
cytokine release assay P07-01P13-20S28-02S28-03
cytokine storm P13-20S28-02
cytokines S03-01OP03-07
cytological study P23-20
cytotoxic P12-29
cytotoxic activity P25-09
cytotoxicit P25-11
cytotoxicity ArrayArrayArrayArrayArrayArrayArrayArrayP07-03P07-06P16-36P16-50P17-03P17-25P17-28
cytotoxicty P10-24
d384 cells P07-08
dairy food chain P12-13
dairy industry P12-13
daphnia magna P17-17
dapsone P04-09
dart P10-10
data analysis Symp01-01
data harmonization P05-25
data quality P19-30
database P01-33P12-30
databases CEC3-01CEC3-05
death P25-24
decision tree P05-15
deep learning P05-20
deficient plasma P06-02
defined approach (da) P01-15
definition of overexpression P03-07
degradability P12-21
deha P19-07
dehp P08-12P10-01
delayed-type hypersensitivity P02-12
dendritic cells P13-01
deoxynivalenol P10-24P13-02
depression P20-12
dermal absorption P12-27
dermal delivery P24-07
dermatology P04-09
development P20-04P20-11S15-01
developmental P06-14
developmental and reproductive toxicity (dart) S23-01
developmental immunotoxicity S25-02S25-04
developmental neurotoxicity P01-36P07-13P12-34P20-13S06-03OP01-07
developmental neurotoxicity study P25-26
developmental origin of health and diseases S13-05
developmental origins of health and disease P25-15
developmental tox S02-05
developmental toxicity P01-08P16-45P17-19S17-03S23-04OP02-01
developmental toxicology ArrayArrayArrayArrayP10-14S23-03
developmental toxicology. P20-03
developmental/reproductive toxicity EU-ToxRisk-1
dgat1 inhibitor P06-11
di-(2-ethylhexyl) phthalate (dehp) P08-13
diabetes P16-27P23-12
diabetes mellitus P23-07
diabetic nephropathy P02-09
diabetic neuropathy P25-40
diazinon. P17-21
dichloroethane (dce) P11-06
dienestrol P08-05
diesel P02-06
diesel exhaust particles P22-07
diet-induced obesity P01-23
dietary intake ArrayArrayArrayArray
dietary pesticide exposure P10-02
differentiated h9c2 cells ArrayArrayArrayArray
dili P05-28
dinitrophenol P16-24
dioxin P01-11P23-15S03-05
diphenhydramine poisoning P04-01
diphenylcyanarsine P12-05
direct-peptide-reactivity-assay P05-07
discovery safety P16-10Symp01-08
disease S19-01
disease-in-a-dish CEC4-04
disinfection by-products P12-17P12-37
dispersion method P17-10
dit S25-03
dmso P18-03
dna adduct P11-15
dna adducts P16-19P16-47
dna and rna (hydroxy)methylation OP01-01
dna damage P12-36P16-41P17-11P17-23S22-04
dna methylation P17-22
dna microarray P19-20P20-03
dna-adducts P11-21
dncb OP01-10
dnel P12-06
dnt P07-23OP01-09
dohad S13-05
dopamin d2 ArrayArrayArrayArray
dopaminergic P06-14
doping P25-13
dose P04-09
dose response CEC3-06OP02-10
dose-response CEC1-04CEC2-03
dose-response analysis CEC2-05
dose-response modelling CEC2-01
dose-response models CEC2-02
doxorubicin P03-12P11-23
doxorubicinol ArrayArrayArrayArray
dpra P01-22
dr-calux P08-01
draize eye test reference database P01-26
drinking water P12-17P12-48P19-16
drinking water quality standard P12-15
drosophila melanogaster P16-31
drug ArrayArrayArrayArray
drug delivery P25-40
drug development KN 2P19-13P19-15S12-01S04-02
drug discovery KN 2P07-43S12-01
drug effect P19-18
drug induced liver injury P05-05
drug induced vascular injury P06-12
drug matabolism P19-20
drug metabolising enzymes P06-28
drug metabolism P07-42
drug profiling S01-04
drug repurposing S12-02
drug safety S24-02Symp01-02Symp01-03
drug safety test P19-20
drug transport P07-02P07-42
drug transporters P06-23
drug-drug interaction ArrayArrayArrayArrayArrayArrayArrayArray
drug-induced kidney injury P23-19
drug-induced liver injury P05-28S21-04S06-02
drug-induced liver injury (dili) OP01-04
drug-induced liver nijury P16-33
drug-induced tissue injury CEC4-04
drug-induced toxicity P01-07
drugs S16-02
drugs of abuse P19-04
dust P12-11
dwnts P17-16
dynamic effects P05-10
e-cigarette P07-10P07-21P18-13
e-cigarette liquids P25-29
e-cigarettes P01-31P19-17
e-liquids P22-09
e-s coupling P20-13
e. coli antibiotic resistance P12-41
e171 P10-12
e551 P17-15
eagle P25-01
early-life S13-04
ecetoc P18-02
ecg P25-21S24-01
echa P12-06
echinacea purpurea P12-24
ecological S14-03
ecological hazard P17-20
ecological health P12-23
ecological risk assessment S14-04
ecological risks P12-50
ecotox S09-04
ecotoxicological assessment P12-40
ecotoxicology P05-15P12-04S18-03
ecvam survey P01-09
edcs S27-01
eds P24-11
eeg S20-02
effectopedia CEC6-02
efficacy P06-03P25-37
eggs P25-20
electronic cigarette P05-12
elemicin P11-15
ellipticine P03-09
embryo P16-22
embryonic stem cell test P07-15
embryonic stem cells P07-13
embryotoxicity P01-03OP02-01
emergency response P25-05
emerging contaminants P25-20
enantioresolution ArrayArrayArrayArray
enantioselectivity ArrayArrayArrayArray
endocrine disrupting chemicals S27-03S27-04
endocrine disruption ArrayArrayArrayArrayS27-02OP02-08
endocrine disruptor P08-02P08-05P08-10P20-10
endocrine disruptors P08-09P25-15
endocrine-disrupting chemicals P08-03
endometriosis P08-04
endothelial migration P22-06
endothelial nitric oxide synthase uncoupling P16-27
energy drink P23-22
engineered nanoparticles S08-03
enhancer P01-16
environment P04-04P12-03
environmental assessment S18-01
environmental chemicals OP02-07
environmental decontamination P25-05
environmental exposure P09-04
environmental medicine P25-15
environmental risk assessment (era) P19-26
environmental tobacco smoke P02-13
environmental toxicology P12-06
enzymatic activity P12-44
enzymes P12-38
eogrts P08-03S25-02S25-03S25-04
epiairway P07-24
epidemiology P19-23
epiderm P07-45
epigenetic P08-02
epigenetic changes OP01-01
epigenetics P03-06P06-09P16-14P17-22P18-03P18-12S27-03
epigenomics P17-22
er-stress ArrayArrayArrayArray
erasmus+ P25-22
ercc5 P11-27
ergotamine P16-01
esbls P12-41
essential elements P04-04
estrogen receptor P08-07
ethanol ArrayArrayArrayArray
eu clp/ un ghs classification P25-17
euphrasia officinalis P12-24
euromix OP02-09
european registered toxicologist P25-16
evotec P16-42
ex vivo assessment P19-18
experimental models P25-25
exploiting new scientific understanding S02-02
exposure ArrayArrayArrayArrayArrayArrayArrayArrayP01-28P10-05P12-27P12-29P12-33P19-08P24-15S08-04
exposure assessment P10-22
exposure assessment. P08-13
exposure model P12-36
exposure modeling CEC1-06P24-13
exposure models CEC1-06
exposure system P25-07
extended one-generation reproductive study P08-03
extended one-generation reproductive toxicity study S25-04
eye P05-11
eye irritation P01-26P07-28P25-17
fat burners P16-24
fatty acid P06-11
fatty acids P25-10
fda P19-01
fe3o4nps P07-08
feathers P25-01
feed P10-23
fertility P20-07OP02-07
fertility assessment P08-10
fetal development P05-24
fetal ovary P20-04
fibroblasts P03-09
fibrosis P16-12S03-01
fih starting dose S04-04
fine particulate matter air pollution P13-08
finished cosmetics products P01-20
fipronil P12-52
first-in-human (fih) P19-15
fischer 344 rat P11-06
fish P02-01
fish embryo S14-01
fish toxicity P05-26
fitc P23-18
flavours P05-12
flipr Symp01-04
fluctuation ames assay P11-19
fluoride P16-06
fluoro-beta-alanine ArrayArrayArrayArray
fluoroquinolones S21-04
fluoxetine P06-14
food ArrayArrayArrayArrayP10-05P10-25P10-26P12-48S18-02
food additives P10-14P12-49
food allergy P13-02
food and chemical safety P10-10
food chain P12-50
food contact materials P10-16P12-48
food contaminant P10-13
food contaminants P10-03
food packaging material P05-02
food raw material P10-15
food safety CEC3-01P10-02P10-06P10-07P10-15P10-27P10-29P12-39P24-08S09-03
food supplement P10-20
foodborne pathogen P10-17
foodstuff ArrayArrayArrayArray
formaldehyde P11-21P12-48
fragrance oils P25-35
free access platforms S09-04
free concentration P25-04
freely available CEC3-06
funding P19-05
fxr activation P07-48
g protein-coupled receptor ArrayArrayArrayArray
g-csf P25-12
gabapentin P04-10
galleria ArrayArrayArrayArray
gard ArrayArrayArrayArrayP07-09P07-36P19-29
gastric damage P13-22
gastro-intestinal Symp01-10
gc-ms ArrayArrayArrayArrayArrayArrayArrayArrayP05-12P12-17P25-20
gcn2 S03-04
gene expresion OP03-02
gene expression P17-22P18-10
gene expression profiling P02-10
gene mutation P11-15
gene network P18-09
gene-specific dna methylation P18-12
general toxicity P10-18
generic models CEC3-01
generic pbk-model P24-05
genetic characteristics P10-17
genetic toxicity P11-18
genetics P25-14
genome editing CEC4-04OP01-08
genome wide transcriptome P16-05
genomic allergen rapid detection P07-36
genotoxic S22-04
genotoxic damage P11-13
genotoxic effect P11-03
genotoxic effects P11-04
genotoxicity P02-01P05-09P05-12P05-16P11-01P11-05P11-09P11-10P11-12P11-14P11-16P11-17P11-19P11-22P11-25P12-01P12-37P17-22P17-23P17-25P17-26P17-28OP03-05
gibberellins P08-11
glia P01-04OP01-03
glioblastoma P03-13
global chemical policy S26-03
glu/gal P16-42
glur2 receptor P05-21
glutathione P16-33P16-41P22-06OP01-01
glycol ethers P24-05
glycolysis ArrayArrayArrayArray
glyphosate P23-03
gmo safety assessment P03-11P13-14
goblet cell hyperplasia P07-24
gonadotoxicity P20-06
gpr124 ArrayArrayArrayArray
grain stocks P10-04
granulosa cells P20-08
graphene P17-06
graphene platelets P17-03
greenscreen P25-34
groundwater P12-40
gst genotypes P11-13
guidance P18-02P19-30
guidance document P19-09
guideline P25-16
gut barrier P13-02
gut-on-a-chip P01-11
h-clat P01-15P01-17P01-22
h9c2 P04-06
h9c2 cells ArrayArrayArrayArray
haccp P10-15
haemocompatibility P02-05
hair P04-04P25-31
hair dye P13-19
hairdresser P13-19
hairless P23-15
hazard Symp01-03
hazard assessment P19-02OP02-10
hazard identification P25-34S02-02
hbel P12-04
hcb P08-04P16-30
health risk P12-26
health risk assessment P19-16
health-risk assessment P02-06
healthcare worker P12-29
heavy metals P12-26
hek293- cells P20-05
hemangiosarcoma Symp01-09
heme iron S11-02
heparg P06-21OP01-04OP02-09
hepatic Symp01-03
hepatic development markers ArrayArrayArrayArray
hepatic differentiation P06-17
hepatic toxicity P01-07
hepatocarcinogenic P16-32
hepatocellular carcinoma P05-22
hepatocyte P19-20
hepatocytes P01-07P06-23P07-05P07-19S06-01
hepatopac P07-40
hepatorenal inflammation response P13-10
hepatotoxicants P01-24
hepatotoxicity ArrayArrayArrayArrayP01-24P05-20P06-21P07-14P07-26P07-48P10-11P16-20P25-22S06-01S06-04Symp01-03
hepatotoxicty P24-04
hepatoxicity ArrayArrayArrayArray
hepg2 P06-22
hepg2 bac-gfp cell stress reporter P07-34
hepg2 cells P07-26P10-24
herbal P22-05
herg KN 2
heuristics Opening-5
hexachlorobenzene P03-02P03-03
hierarchical clustering ArrayArrayArrayArray
hif-1a P16-16
high content P12-02
high content analysis P06-15Symp01-08
high content imaging ArrayP06-21ArrayS08-01
high content imaging platform P16-25
high content imaging. P23-14
high content screening P07-10
high fat diet P16-14
high throughput P12-02P18-11
high throughput sequence P16-05
high-content imaging P16-49
high-throughput screening P07-38
highly volatile substance P01-26
hipsc P06-15P07-46
histopathology P19-06P22-01
historical negative control data P11-26
hk-2 cells P23-06
hlc S06-01
hopoxia-cultured P19-24
horizon 2020 CEC1-02
hpg axis P24-11
hplc-fld P10-27
hplc-ms/ms P16-47
hprt assay P11-26
hse P17-20
hsspme-gc/ms P25-31
hu5c8 S01-03
human P05-16P07-38P07-40P13-18P20-04S14-03
human biomonitoring P09-04P24-12
human bipotent liver stem cells P07-17
human disease S25-01
human exposure ArrayArrayArrayArrayP12-20
human fetal liver P06-28OP02-08
human hair P12-07
human health P12-23S14-04
human health assessment P12-40
human health hazard P17-20
human health risk assessment P12-50
human hepatocytes P07-48
human in vitro testing OP03-06
human induced pluripotent stem cells P06-12P07-29
human ips cell P19-20
human ips cells OP01-08
human lymphocytes P17-09
human milk oligosaccharide P10-29
human neonatal mesenchymal stem cells P03-12P25-12
human progenitor cells P12-34
human reconstructed skin OP03-01
human relevance ArrayArrayArrayArrayS22-03
human relevance framework P16-32
human relevant P19-05
human risk assessment P05-13S18-02
human safety P12-02
human skin-derived precursors S06-02
human toxicology CEC4-04P05-15
human variability P24-10
human volunteer study P24-12
human-induced pluripotent stem cell-derived cardiomyocytes P23-04
humanized mouse models S28-01
humoral immunity S03-03
hupa-plga-nps P24-02
huperzine a P10-20
huperzinea P24-02
hydra attenuate P01-29
hydratation of skin P01-30
hydrogel P07-19
hydrogen fluoride P12-18
hydroperoxides P16-18
hydroquinone analogues P07-34
hydroxylated pcb P08-07
hydroxynonenal S11-02
hydroxytyrosol P13-22
hypersensitivity OP03-06
hyperthermia P06-26
hyperuricemia P04-02
hypothermia P23-05
hypoxic ischemic encephalopathy ArrayArrayArrayArray
iata P19-21S23-02
iberoamerican P25-06
iccr S02-06
ice P07-39
icp-ms P04-04P25-01
idiosyncratic toxicity CEC4-06
ido S03-04
ido-1 P13-21
il-12 cytokine family P13-01
il-13 P07-24
il-18 P07-30OP03-01
il6 K-01
image-based morphology profiling P16-49
imminotoxicity S03-02
immune modelling P13-18
immune response S07-04
immune status P13-14
immune system P09-02P17-12
immune system response P13-12
immunhistochemistry P03-07
immunoassay P02-14
immunogencicty OP03-06
immunogenicity P13-18P19-28
immunometabolism P13-21
immunomodulation S16-01S07-03
immunomodulatory compound P13-20
immunomodulatory drugs IND 1-1
immunopharmacology S04-03
immunosuppression P02-12P13-06S21-02S03-01OP01-02
immunosuppressive responses S03-01
immunotherapy S12-03
immunotoxicity S16-03S28-02OP03-06
immunotoxicological studies P13-14
immunotoxicology ArrayArrayArrayArrayP13-20P13-23S16-02S03-03S03-05S04-03
impaired wound healing P25-12
impedance P07-32
in chemico P01-10P01-25
in silico P01-10P01-19P01-25P05-01P05-06P05-07P05-09P05-18P05-21P10-16P12-21P12-42P19-05P22-10OP02-01
in silico allergen prediction model P01-13
in silico methods OP02-06
in silico modelling CEC3-05
in silico screening P05-02
in silico skin penetration model P24-07
in silico tools P12-10
in utero exposure P02-13
in vitro P01-10P01-12P01-14P01-18P01-25P01-28P05-16P06-14P06-27P07-05P07-06P07-10P07-13P07-23P07-24P07-36P07-41P07-46P07-48P12-02P12-32P12-34P13-18P16-42P17-22P17-26P18-06P19-05P19-29P22-05P22-06P23-09S01-01S17-03S04-03S08-04OP02-09OP03-01OP03-05OP03-07OP03-10
in vitro toxicity P01-24
in vitro aerosol exposure P25-07
in vitro airway models P07-25
in vitro assay P01-07P01-21P07-36S28-03
in vitro assay development ArrayArrayArrayArray
in vitro assays P01-20P07-14S06-05OP02-02
in vitro assessment P22-02P22-09
in vitro bbb models P07-29
in vitro biokinetics P25-04
in vitro dmpk P24-15
in vitro dose response CEC3-03
in vitro eye irritation testing strategy P07-28
in vitro hepatotoxicity P07-40S06-02
in vitro in vivo extrapolation (ivive) S08-03
in vitro lung model P07-22
in vitro lung models CEC4-03
in vitro metabolism P16-20
in vitro method ArrayArrayArrayArray
in vitro methods P01-22P19-21S02-02OP01-05
in vitro model CEC4-01P01-16P01-34P07-02P07-07
in vitro models P06-12P07-31S18-02S07-04
in vitro moisturization test P01-30
in vitro neurotoxicology P07-18
in vitro reconstructed tissue model P07-42
in vitro screening P07-08P17-06
in vitro sensitization P07-21
in vitro testing P23-14S03-03S08-02
in vitro toxicity ArrayArrayArrayArrayP16-46P17-18P19-17P23-16
in vitro toxicity testing OP01-09
in vitro toxicity tests S02-03
in vitro toxicology ArrayArrayArrayArrayP01-03P06-21S01-04
in vivo P01-32P10-14P10-25P11-25P18-06
in vivo genotoxicity P11-06
in vivo mutagenicity P11-14
in-silico toxicology P05-08
in-vitro P01-02P07-20
in-vitro cellular assay P13-20
in-vitro screening S02-04
in-vitro toxicity P05-08
in-vitro toxicology P07-11
incubator microscope S07-02
ind IND 2-1
indomethacin P13-22
indoor air quality P25-38
induced pluripotency P25-25
induced pluripotent stem cells P12-34
induction ArrayArrayArrayArray
induction/activation ArrayArrayArrayArray
inductively coupled plasma mass spectrometry ArrayArrayArrayArray
infant formula P10-29
infection S07-01
infertility P20-09
inflammasome P16-15P17-03S21-01
inflammation K-01P01-01P07-35P16-12P17-19P25-18S11-05S21-02S21-04S07-01OP01-03OP03-02
inflammatory bowel disease P07-37
inhalation P01-28P12-11P17-06
inhalation exposure P12-11P12-18
inhalation toxicity CEC4-03
inhalation toxicology P07-25P12-43P19-06
inhaled particles P17-14S21-02
innate immune P13-07
innate immunity P07-37S21-01S21-03OP01-10
innate immunology P13-13
inos P16-17P25-18
input data CEC2-05
insecticide P10-28
insecticides residues P10-04
insectivorous passerines P02-11
integrated aop P07-16
integrated approaches to testing and assessment (iata) P19-30S23-01
integrated testing P01-05P11-14
integrated testing and assessment strategies S02-03
interaction P16-36
interactions P24-08
interferon gamma P13-21
internal ttc CEC3-04
international chemicals management S26-03
interoperability P05-25P19-25
intestinal absorption P01-16
intestinal fibrosis P07-07
intestinal inflammation P07-37
intestinal organoid P07-07
intestinal organoids P25-25
intestinal permeability P17-15
intestinal toxicity P07-37
intra-individual variation P24-12
intratracheal instillation P17-19
intravenous exposure P19-07
intraventricular dose ArrayArrayArrayArray
intubation and ventilation P06-13
investigative toxicology Symp01-08
ion channel S24-03
ip-lc/ms P23-19
ip346 P19-22
ips cells P01-03P07-07
ips-derived cardiomyocytes P16-44
ipsc S06-03
ipscs ArrayArrayArrayArray
ir rays P11-22
iron alloys P16-04
iron oxide nanoparticles P17-17
irritant-induced asthma P13-13
irritation P05-11
iso-ompa P16-38
isoflurane P06-24
isolated chicken eye P07-39
isoparrafin P25-34
isoprothiolane P12-51
ivive P01-12S09-01
jtp and tpe intervals P25-21
jtpeak qtc concentration-response S24-01
justificationnew appr CEC5-03
juvenile S15-01
juvenile animal S15-03S15-04
juvenile toxicity studies S15-02
k562 P25-03
keap1-nrf2 S11-05
keratinocyte P07-30
keratinocytes P23-15
keywords: safe innovation P17-20
kidney P05-06P07-02P18-05P23-16P23-19S19-03
kidney organoids P16-10
kidney stone P25-39
kinase inhibitors P06-16
kindey P24-15
kinetic modeling CEC3-03
kinetically derived maximum dose ArrayArrayArrayArray
kl001 P06-24
knime S09-02
knock-out rats P16-45
kupffer cells ArrayArrayArrayArray
kynurenic acid P13-09
l-glutamic acid-g-p(hema) P17-18
label-free P07-32
label-free proteome analysis P01-13
labeling P25-29
laboratory animals P19-10P20-07
lambda cyhalotrin P11-19
lambda-cyhalothrin P02-03
land use regression models S13-01
larval phase P12-44
lay people Opening-5
lc-ms/ms P10-27P24-02
leacheable compounds P08-09
lead P25-01
lebanese pita P12-20
leicestershire P12-41
leukocytes S21-04
levamisole P06-27
licl P19-10
life-course exposure P12-28
ligand based modeling P05-04
linc-ror P03-10
line-1 P03-02
linear mixed model P12-03
lipid P16-18
lipid peroxidation P02-11P16-29P16-36P23-12
lipopolysaccharide P13-22S07-03
liposomes P06-04
liquid chromatography-mass spectrometry OP01-04
lithium chloride P19-10
lithium ion P12-18
lithium salt P20-07
liver CEC4-01CEC4-06P02-10P05-18P07-05P16-23P16-32P16-34P18-05P23-05P25-22S01-02S14-02S06-01OP01-05Symp01-03
liver injury P01-24P07-34
liver mitochondria P23-12
liver regeneration P25-23
liver sinusoidal endothelial cells P01-07
liver spheroids P07-11
liver toxicity ArrayArrayArrayArrayArrayP05-28P06-20ArrayS08-01
liver-chip P07-43OP03-04
livestock P13-07
llna P12-45
loael P12-05
locomotor behavior P25-41
long-term incubation P07-40
lps P07-01OP03-02
lung P12-43P16-12
lung alveolus-on-chip OP03-08
lung barrier P13-13
lung cancer P03-07P07-22
lung cells P22-07
lung fibrosis P16-37P16-40
lung function P19-27
lung toxicity CEC4-03
lung-on-chip P07-35OP03-08
lush prize P19-05
lycopene P23-17P23-20P23-21
lysosomal overload P23-14
lysosome P06-05
lysosomotropism P06-05
mab S04-01
machine learning P05-04P05-08
machine-learning OP02-06
macrophage P13-11P13-22
macrophages P12-12P13-06P25-18OP01-02
maestro edge ArrayArrayArrayArray
maestro pro ArrayArrayArrayArray
male fischer 344 rats P17-05
male rats P08-05P08-06
male reproduction OP02-02
malondialdehyde P16-41
mammary epithelial cells P11-06
management guidelines P19-19
manganese P01-04OP01-03
mannich bases P25-09
marconi P20-05
margin of exposure S22-02
marine mammal P07-06
mass spectrometry P02-14P10-23P16-19
mass spectrometry-based immunoassay P23-19
maternal exposure. P08-05
maternal smoking P06-28OP02-08
mathematical modeling S09-02
mathematics HESI CITE-1
mature human neurons P07-31
mda-mb-231 P06-22
mdm2 P03-10
mdma P04-06
mea ArrayArrayArrayArrayP07-46P12-32Symp01-04
mean platelet volume P06-08
measured data S18-03
mechanism of toxicity P07-43P16-46
mechanisms of toxic action P05-15
mechanisms of toxicity P16-35
mechanistic toxicology P11-16S14-02
mechanosensory P01-06
medical device ArrayArrayArrayArrayP01-12P13-04
medical devices P08-09
medical school education P25-15
medicinal plant P11-08
medicinal plants ArrayArrayArrayArray
medicine HESI CITE-1
medicine residues P12-31
medicines ArrayArrayArrayArray
meknes P12-46
membrane components P17-09
membranolysis P16-15
menstrual disorders P20-10
menthol P19-06
merit P18-02
mesenchymal stem cells ArrayArrayArrayArray
mesothelioma P13-06OP01-02
meta- analysis P10-26
metabolic activation P10-03P11-07P13-08
metabolic activity P07-04
metabolic biomarkers OP02-01
metabolic disorders P18-08
metabolic processes P12-06
metabolism K-01P10-19P10-24P12-06P19-12P25-04S03-01Symp01-03
metabolism intensity P19-10
metabolome analysis in vitro P07-26P18-07
metabolomics ArrayArrayArrayArrayArrayArrayArrayArrayP18-02S08-01OP01-04
metal complexes P25-09
metal mixtures P16-50
metal oxide nanoparticles P22-07
metaldehyde P25-27
metallic trace elements analysis P12-20
metals P01-14P02-11P04-04P08-14OP02-10
metaproteomics S18-01
metformin P13-09
methamphetamine ArrayArrayArrayArray
methemoglobin P04-09
method evaluation S02-03
methodologies S24-04
methyl mercury P13-09
methylmercury P16-29
methylone ArrayArrayArrayArray
mice P12-45P13-13P18-09
microarray P12-03
microbead sensors P07-04
microbial purification P25-38
microbiology P12-39
microbiome S18-01S03-05
microbiota P03-01P13-07
microbrain Symp01-04
microcystin P10-08
microcystin-lr P11-10
microelectrode array ArrayArrayArrayArray
microencapsulation P25-40
microextraction by packed sorbent P25-20
microfluidic P07-11
microfluidic culture system P07-17
microfluidics P01-11P06-17S06-04S07-02
microglia S12-03
micronuclei P17-11
micronuclei structures P11-03
micronucleus P10-25P11-25P17-24
micronucleus assay P11-13
micronucleus in vivo P11-02
micronucleus test P11-10P11-18P11-19
microorganisms P25-38
microphysiological systems S01-01OP03-04
microrna K-01P02-06P18-03
micrornas S19-04OP01-06
microsomal metabolism P16-47
microtissue P07-05
microtissues OP03-02
midbrain P06-14
migraine P16-01
mineral mix composition P20-07
mineral oil P19-22
minigut Symp01-05
mining area P09-01
minipig P02-10
mipafox P16-38
mir-204 P03-10
mir-6126 P16-37
mirna P13-08
missing factors P06-02
mitochondria ArrayArrayArrayArrayP16-23P16-44P23-09S10-01S10-02
mitochondrial dyfunction Symp01-06
mitochondrial dysfunction P05-28P16-20
mitochondrial oxidative stress P13-09
mitochondrial permeability transition P23-12
mitochondrial toxicity P05-04P07-14P16-42S10-04
mitotic index P17-24
mitotoxicity ArrayArrayArrayArray
mixture CEC1-03P04-06P22-04P22-08S27-03
mixture effects ArrayArrayArrayArrayArrayArrayArrayArray
mixture toxicity P17-17P22-07
mixtures CEC1-04ArrayArrayArrayArrayP22-10S14-03S27-02
mmp P16-42
moah P19-22
mode of action ArrayArrayArrayArrayP16-32P16-45P18-07P20-05S22-03
model ArrayArrayArrayArrayP05-11
model animal OP01-07
model averaging CEC2-02
modelling CEC3-06CEC6-03P24-08
molecular docking P05-02P06-02P06-06
molecular initiating event (mie) P05-13
molybdate P16-34
molybdenum(iii) P11-01
mongolia P09-01
monitoring P02-15P12-07S19-03
monkey S04-02
monoclonal antibodies S04-01OP03-06
monoclonal antibody S04-04
monocytes S21-02
monotoring P04-09
mooc P25-22
mop P24-14
mouse P13-16P16-07P23-09
mouse embryonic stem cells P23-08
mouse hepatocytes P11-27
mps Symp01-03
mri P19-03S13-04
mrna P07-47
mrna translation P11-27P18-10
mtor S03-04
muc 1 P03-07
multi-constituent substance CEC5-02
multi-omics P08-14
multipotent stem cells S06-02
multiwalled carbon nanotubes P17-26
mutagenicity P16-47P22-05
mwcnt P17-05
mycoestrogen P22-03
mycosynthesis P16-46
mycotoxin P10-19
mycotoxin-binding agents P10-27
mycotoxins P10-21P10-22P10-23P16-36
myelinaton S06-03
n-butylparaben P08-06P08-10
n-hexane P20-10
n-nitrosamines P12-17
n-nitroso compounds P10-09
nadph oxidase P25-33
nanocarrier P11-23
nanocomposite P17-23
nanomaterial S07-04
nanomaterials P03-09P17-06P17-12P17-13P17-22P17-26S18-02
nanomedicine S16-01
nanoparticle P01-28P17-21
nanoparticles P02-01P10-12P13-21P17-11P17-14P17-22P20-08P24-01S18-01
nanosafety profile P17-07
nanotoxicity P11-23S07-02
nanotoxicology P07-08P13-23
nanotubes P13-06
nash P01-27
natural inhibitors P06-06
naturalness Opening-5
neonatal sprague-dawley rats ArrayArrayArrayArray
neopterin P13-21
nephrotoxicity CEC4-02ArrayArrayArrayArrayP05-06P07-38P08-15P16-06P16-21P18-07P23-06P23-16P23-19P23-22S08-02OP03-09
networks P25-06
neural crest P07-15
neural stem cells P07-18
neuroblastoma P03-09
neurodegeneration P01-04S10-01S12-03
neurodevelopment ArrayArrayArrayArrayP08-14P16-13
neurodevelopmental disorders S27-02
neuroinflammation P01-04P13-15S12-03
neurological changes P12-49
neuropathic pain P04-10
neuropathy S20-03
neuropsychopharmacology S12-04
neurosphere P07-23
neurotoxicity ArrayArrayArrayArrayArrayArrayArrayArrayP06-19P07-08P07-31P07-33P08-12P10-08P16-05P17-04P23-01P23-03S20-01OP01-03
neurotoxicity testing P12-32
neurotoxicology P01-04
neurotoxin P25-10
neutrophils P25-30P25-33
new approach methodology CEC5-03
new approach methods (nams) EU-ToxRisk-1
new psychoactive substances ArrayArrayArrayArrayP16-13
next generation risk assessment S02-06
nf-κb P25-35
nfil-3 P13-01
nhp P19-03
nickel(ii) P11-01
nicotinamide riboside P03-06
nicotine P25-32
nile tilapia P02-03
nitric oxide P03-03
nitronium ion P16-18
nnk P03-04
no P23-17
no2 P12-46
noael P12-05
noael approach CEC2-01
non human primate P02-12
non in vivo P07-12
non-alcoholic fatty liver disease P06-21OP02-08
non-animal CEC3-02P01-18P19-05OP03-07
non-animal alternative methods OP03-03
non-animal methods IND 4-1ArrayArrayArrayArrayP12-35
non-animal testing P01-12
non-clinical safety assessment P01-23Symp01-07
non-clinical toxicities P19-28
non-genotoxic S22-04
non-genotoxic carcinogens P05-22
non-human primates P19-18
non-invasive S19-01
non-parenchymal cells P06-23
non-rodent P19-13
non-steroidal antiinflammatory drugs P25-09
non-us countries P19-01
nonclinical S15-03S05-04
nonclinical safety S04-01
novel food P10-06
nrf-2 S25-03
nrf2 KN 1P25-23S11-01S11-02S11-04S21-03OP01-10
nrf2 pathway P05-05P07-34
nrk-52e cells P18-07
nte P16-38
nuclear factor-kappab OP01-03
nuclear receptors OP03-10
nuclear translocation P06-05
nuclear uptake P17-22
nucleotidases P06-06
obesity and comorbidities P22-08
obesogen P08-02
obesogenic effects P04-08
occludin P01-30
occupational asthma P19-27
occupational exposure P11-22P17-11
occupational exposure limits P19-27
occupational exposure. ArrayArrayArrayArray
occupational health S26-05
oced toolbox P10-10
oct2 P04-10
ocular drug delivery P07-42
ode model P05-05
odes P18-06
oecd P08-03P19-09
oecd 437 P07-39
oecd 438 P07-39
oecd tg 442e P01-15
oel P12-04
off target profiling Symp01-02
office P25-38
older adults P12-28
oleanolic acid P06-22
oligonucleotide P06-08S05-03
oligonucleotides S05-01
omics P01-31P18-03P18-07P18-13P19-25OP01-06
omics analysis P18-05
oncogenic markers P03-11
oncology P19-28
ontogeny P01-34S15-02
ontology ArrayArrayArrayArrayP05-24S23-03
open source S09-03
open water systems P12-41
openfoodtox S09-03
operator P12-27
ophthalmic homeopathic ointment P12-24
opioid P24-14
optimization P01-35
oral ArrayArrayArrayArray
oral cavity cancer P20-01
oral dose toxicity P10-25
oral exposure P10-04S18-02
oral fluid P19-04
organ S15-01
organ on chip CEC4-06
organ-chips S01-02
organ-on-a-chip P01-11P06-20P07-11P07-33P07-43P24-06OP03-04OP03-09
organ-on-chip S01-03
organ-on-chips S06-04
organic solvent metabolite P13-15
organoids CEC4-05P07-18S01-05
organophosphate P17-21
organophosphorus insecticide P06-13
organosilicon compounds P12-14
organotypic culture P01-01
organotypic cultures P01-31
organs on a chip S01-04
organs on chips S01-01
organweights P19-11
ovary P20-08
over-the-counter product P04-01
oxidative degradation P12-31
oxidative potential P12-16
oxidative stress ArrayArrayArrayArrayP05-05P06-09P07-34P08-06P10-13P11-16P12-26P12-44P16-04P16-12P16-20P16-29P16-31P16-43P16-44P23-08P23-10P25-36OP02-06
oxidative stress. P13-10
oxygen consumption P07-14
oxygen sensing P07-04
oxytocin P20-12
p-glycoprotein ArrayArrayArrayArrayArrayArrayArrayArrayP06-22
p53 P03-10
pac P19-22
packaging P25-29
paediatric S15-02S15-04
pah toxicity P16-45
pahs P07-47S22-04
pairwise testing CEC2-01
pan-centromeric fish P17-11
para-brom-benz-thio-hydroxime P25-28
parabens P02-15
paracetamol P19-19P20-04
paraoxon P16-38P25-10
parkinson P12-03
parkinson's disease S12-03
parquat P12-44
particle size P17-02
particles S13-04S03-01
particulate matter P02-06P13-07
passive sampler P12-46
passive samplers. P12-40
patch-clamp S24-03
pathogenic gene profiles P10-17
pathway S14-02
payload P19-28
pb(pk) models S09-02
pbk CEC3-05P05-14
pbk modelling OP02-02
pbk or pbbk or pbtk or pbpk P24-12
pbmc P13-21
pbpk CEC3-06P08-15P24-14
pbpk modeling P08-13
pbpk modelling CEC3-02CEC3-04
pbpk/pd P24-11
pcdd/fs ArrayArrayArrayArray
pcna P11-08
pde P12-04P12-24
peanut P13-02
pediatric S15-01S15-03
peg-serine P17-21
pegylation P13-12
pentedrone and methylone enantiomers ArrayArrayArrayArray
percellome P18-09
perfluoroalkyl substances P20-02S03-03
perinatal exposure P08-10
peripheral blood P20-06
peripheral nervous system S20-03
permanent tumor cell lines P25-09
permeation P01-16
peroxisome proliferator-actiavted receptor alpha S22-03
peroxisome proliferators P16-32
persistent organic pollutants P08-01P25-31OP02-07
personal care products P12-11
personal lubricants P01-12
personalized medicine P11-23
pesticide P11-14P12-40P25-10
pesticide formulations S02-05
pesticide residue P10-02
pesticides P02-14P04-08P11-13P11-19P12-30P12-49P20-06P22-10P25-26S03-02
petroleum products S02-04
pfhxs P19-16
pfos P19-16
pgh P23-18
phagocytosis OP01-10
pharmaceutical ingredients P25-37
pharmaceuticals P03-08P19-26
pharmacodynamics S15-02
pharmacokinetics P04-10P07-29P24-02P24-13P25-25S15-02
phenobarbital P02-10
phenolic benzotriazole P05-17
phenotypic analysis P06-15
phenoxyethanol OP02-04
phenylcapsaicin P10-25
phenylpropenes P16-47
phenylvalerate esterase P16-38
phip K-01
phmb P23-18
phmg P23-18
phmg-phosphate P16-37P16-40
phosphate triester P25-11
phosphite triester P25-11
phospholipid P17-01
photodegradation P06-04
phototoxicity P06-04P07-45
phthalate metabolites P09-03
phthalates P08-14P09-02P22-08P24-05
phuse P19-01
physical exercise P12-28
physicochemical properties P17-25
physiologically based pharmacokinetic (pbpk) modelling S08-03
physiologically-based toxickinetic models CEC3-01
phytochemicals P10-09
pip decisions S15-04
pk/pd Symp01-10
pk/pd relationship S04-04
pkc P25-33
place conditioning P25-08
placenta P20-03
placental growth factor (plgf2) Symp01-09
platelet count P06-08
platelet function P19-18
platelet receptors P06-02
platycodon P10-18
pluripotency P16-48
pluripotent stem cells P01-24
pm0.25 P12-16
pm2.5 P12-08
pmsf P16-38
pnec P12-06
pneumonia P17-16
point of departure P12-25OP02-05
poisoning P25-01
policy support S17-01
polybrominated diphenyl ether P25-20
polychlorinated biphenyls P12-03
polycyclic aromatic compounds S03-03
polycyclic aromatic hydrocarbons P03-01P10-05P11-03P11-04OP01-01
polyethlemine P25-30
polymer biomaterial P02-05
polymethoxyflavones(pmfs) P03-01
polymorphism CEC4-04
pomegranate P23-10
pops P07-06
positive control P25-11
postnatal S15-01
potassium octatitanate fibers P17-05
potency P01-05OP03-07
ppar-gamma P16-10
pparα P16-32
precision cut liver slices (pcls) ArrayArrayArrayArray
preclinical IND 2-1P02-02P13-18S19-04S20-04S05-02
preclinical safety P06-08
preclinical studies Symp01-01
prediction P03-08
predictive P07-38
predictive neurotoxicity testing S08-03
predictive testing S17-02
predictive toxicology P05-08P05-25S23-04
prefrontal cortex P23-01
pregnancy P12-33
pregnant women P02-15P09-03
prenatal programming P16-14OP02-08
prenatal toxicity S13-05
prenatal treatment P20-12
preservative OP02-04
prevalence P10-26
prevention P10-09P23-21
primary mouse hepatocytes ArrayArrayArrayArrayP18-10
printing ink P05-02
pro-inflammation P12-16
proaarhythmia S24-04
proarrhythmia biomarkers P25-21
proarrhythmic risk P25-21
proast CEC2-03CEC2-04CEC2-05P16-22
probabilistic risk assessment P19-16
product label S15-04
profiler P05-06
progesterone P20-08
prohaptens P01-21
proinflammatory cytokines P25-35
prolactin ArrayArrayArrayArray
proliferation P16-16
promoter area P18-12
propaquizafop P16-32
prostate cancer ArrayArrayArrayArray
protective role P23-10
protein aggregation S12-03
protein allergens P01-13P01-19
protein assessment P10-07
proteomics P18-13
proteomics analysis P16-50
protocol P19-02
protocols S03-02
proximal tubule cells P07-38
psyllium P04-02
ptp4a3 P16-16
pulmonary P01-18P12-43
pulmonary inflammation ArrayArrayArrayArray
pyrethroids P16-03
pyrrolizidine alkaloids ArrayArrayArrayArrayP10-03P10-11
qivive P08-15P24-05S08-02
qpcr P01-34
qra OP02-05
qsar P05-09P05-11P05-28
qsar toolbox P05-01
qtc prolongation P25-21
quality assurance P18-02
quantal data CEC2-02
quantification P19-12
quantitative adverse outcome pathways CEC6-03
quantitative aop S23-02
quantitative aops ArrayArray
quantitative risk assessment P13-19
quartz P16-15
quechers P10-23
quercetin P16-01
questionnaires P02-13
r web app CEC2-04
raaf CEC5-01
radioactivity P19-12
radioprotective effect P07-03
randomised controlled trial P06-13
ranking P16-22
rapamycin P02-12
rapid risk assessment P12-39
rapid screening P19-04
rar P20-05
rare disease P11-02S12-02
rare earth metals P12-07
rat P02-02P16-05P19-07P23-01P23-09P25-08P25-24
rat erythroleukemia P25-03
rat liver P16-03OP01-01
rats P10-25P17-04
reach CEC5-01CEC5-02CEC5-05ArrayArrayArrayArray